Inter-fraction dynamics during post-operative 5 fraction cavity hypofractionated stereotactic radiotherapy with a MR LINAC: a prospective serial imaging study.


Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 30 10 2021
accepted: 27 12 2021
pubmed: 5 1 2022
medline: 30 3 2022
entrez: 4 1 2022
Statut: ppublish

Résumé

This study examined changes in the clinical target volume (CTV) and associated clinical implications on a magnetic resonance imaging linear accelerator (MR LINAC) during hypofractionated stereotactic radiotherapy (HSRT) to resected brain metastases. In addition, the suitability of using T2/FLAIR (T2f) sequence to define CTV was explored by assessing contouring variability between gadolinium-enhanced T1 (T1c) and T2f sequences. Fifteen patients treated to either 27.5 or 30 Gy with five fraction HSRT were imaged with T1c and T2f sequences during treatment; T1c was acquired at planning (FxSim), and fraction 3 (Fx3), and T2f was acquired at FxSim and all five fractions. The CTV were contoured on all acquired images. Inter-fraction cavity dynamics and CTV contouring variability were quantified using absolute volume, Dice similarity coefficient (DSC), and Hausdorff distance (HD) metrics. The median CTV on T1c and T2f sequences at FxSim were 12.0cm Statistically significant reductions in cavity CTV was observed during HSRT, supporting the use of MR image guided radiation therapy and treatment adaptation to mitigate toxicity. Significant CTV contouring variability was seen between T1c and T2f sequences. Trial registration NCT04075305 - August 30, 2019.

Identifiants

pubmed: 34981300
doi: 10.1007/s11060-021-03938-w
pii: 10.1007/s11060-021-03938-w
doi:

Banques de données

ClinicalTrials.gov
['NCT04075305']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

569-577

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494–500
doi: 10.1056/NEJM199002223220802
Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol 29(2):134–141
doi: 10.1200/JCO.2010.30.1655
Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037–1044
doi: 10.1016/S1470-2045(09)70263-3
Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK et al (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316(4):401–409
doi: 10.1001/jama.2016.9839
Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P et al (2017) Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1040–1048
doi: 10.1016/S1470-2045(17)30414-X
Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC et al (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1049–1060
doi: 10.1016/S1470-2045(17)30441-2
Soliman H, Myrehaug S, Tseng CL, Ruschin M, Hashmi A, Mainprize T et al (2019) Image-guided, linac-based, surgical cavity-hypofractionated stereotactic radiotherapy in 5 daily fractions for brain metastases. Neurosurgery 85(5):E860–E869
doi: 10.1093/neuros/nyz162
Eitz KA, Lo SS, Soliman H, Sahgal A, Theriault A, Pinkham MB et al (2020) Multi-institutional analysis of prognostic factors and outcomes after hypofractionated stereotactic radiotherapy to the resection cavity in patients with brain metastases. JAMA Oncol 6(12):1901
doi: 10.1001/jamaoncol.2020.4630
Soliman H, Ruschin M, Angelov L, Brown PD, Chiang VLS, Kirkpatrick JP et al (2018) Consensus contouring guidelines for postoperative completely resected cavity stereotactic radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 100(2):436–442
doi: 10.1016/j.ijrobp.2017.09.047
Eaton BR, LaRiviere MJ, Kim S, Prabhu RS, Patel K, Kandula S et al (2015) Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neurooncol 123(1):103–111
doi: 10.1007/s11060-015-1767-4
Specht HM, Kessel KA, Oechsner M, Meyer B, Zimmer C, Combs SE (2016) HFSRT of the resection cavity in patients with brain metastases. Strahlenther Onkol 192(6):368–376
doi: 10.1007/s00066-016-0955-2
Minniti G, Esposito V, Clarke E, Scaringi C, Lanzetta G, Salvati M et al (2013) Multidose stereotactic radiosurgery (9 Gy x 3) of the postoperative resection cavity for treatment of large brain metastases. Int J Radiat Oncol Biol Phys 86(4):623–629
doi: 10.1016/j.ijrobp.2013.03.037
Teyateeti A, Brown PD, Mahajan A, Laack NN, Pollock BE (2020) Brain metastases resection cavity radio-surgery based on T2-weighted MRI: technique assessment. J Neurooncol 148(1):89–95
doi: 10.1007/s11060-020-03492-x
Hall WA, Paulson ES, van der Heide UA, Fuller CD, Raaymakers BW, Lagendijk JJW et al (2019) The transformation of radiation oncology using real-time magnetic resonance guidance: A review. Eur J Cancer 122:42–52
doi: 10.1016/j.ejca.2019.07.021
de Mol SR, van Otterloo CJP, Blezer ELA, Akhiat H, Brown K, Choudhury A et al (2021) Patterns of Care, tolerability, and safety of the first cohort of patients treated on a novel high-field mr-linac within the momentum study: initial results from a prospective multi-institutional registry. Int J Radiat Oncol Biol Phys 111:867–875
doi: 10.1016/j.ijrobp.2021.07.003
Sneed PK, Mendez J, Vemer-van den Hoek JG, Seymour ZA, Ma L, Molinaro AM et al (2015) Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg 123(2):373–386
doi: 10.3171/2014.10.JNS141610
Cao Y, Tseng CL, Balter JM, Teng F, Parmar HA, Sahgal A (2017) MR-guided radiation therapy: transformative technology and its role in the central nervous system. Neuro Oncol 19(2):ii16–ii29
doi: 10.1093/neuonc/nox006
Mutic S, Dempsey JF (2014) The ViewRay system: magnetic resonance-guided and controlled radiotherapy. Semin Radiat Oncol 24(3):196–199
doi: 10.1016/j.semradonc.2014.02.008
Fallone BG (2014) The rotating biplanar linac-magnetic resonance imaging system. Semin Radiat Oncol 24(3):200–202
doi: 10.1016/j.semradonc.2014.02.011
Alghamdi M, Hasan Y, Ruschin M, Atenafu EG, Myrehaug S, Tseng CL et al (2018) Stereotactic radiosurgery for resected brain metastasis: Cavity dynamics and factors affecting its evolution. J Radiosurg SBRT 5(3):191–200
pubmed: 29988304 pmcid: 6018046
Scharl S, Kirstein A, Kessel KA, Duma MN, Oechsner M, Straube C et al (2019) Cavity volume changes after surgery of a brain metastasis-consequences for stereotactic radiation therapy. Strahlenther Onkol 195(3):207–217
doi: 10.1007/s00066-018-1387-y
Atalar B, Choi CY, Harsh GRT, Chang SD, Gibbs IC, Adler JR et al (2013) Cavity volume dynamics after resection of brain metastases and timing of postresection cavity stereotactic radiosurgery. Neurosurgery 72(2):180–185
doi: 10.1227/NEU.0b013e31827b99f3
Jarvis LA, Simmons NE, Bellerive M, Erkmen K, Eskey CJ, Gladstone DJ et al (2012) Tumor bed dynamics after surgical resection of brain metastases: implications for postoperative radiosurgery. Int J Radiat Oncol Biol Phys 84(4):943–948
doi: 10.1016/j.ijrobp.2012.01.067
ClinicalTrials.gov. Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease. NCT04114981. Assessed Nov 2021 [
Wernicke AG, Hirschfeld CB, Smith AW, Taube S, Yondorf MZ, Parashar B et al (2017) Clinical outcomes of large brain metastases treated with neurosurgical resection and intraoperative cesium-131 brachytherapy: results of a prospective trial. Int J Radiat Oncol Biol Phys 98(5):1059–1068
doi: 10.1016/j.ijrobp.2017.03.044
Ahmed S, Hamilton J, Colen R, Schellingerhout D, Vu T, Rao G et al (2014) Change in postsurgical cavity size within the first 30 days correlates with extent of surrounding edema: consequences for postoperative radiosurgery. J Comput Assist Tomogr 38(3):457–460
doi: 10.1097/RCT.0000000000000058
Faruqi S, Ruschin M, Soliman H, Myrehaug S, Zeng KL, Husain Z et al (2020) Adverse radiation effect after hypofractionated stereotactic radiosurgery in 5 daily fractions for surgical cavities and intact brain metastases. Int J Radiat Oncol Biol Phys 106(4):772–779
doi: 10.1016/j.ijrobp.2019.12.002
Kohutek ZA, Yamada Y, Chan TA, Brennan CW, Tabar V, Gutin PH et al (2015) Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. J Neurooncol 125(1):149–156
doi: 10.1007/s11060-015-1881-3
Milano MT, Grimm J, Niemierko A, Soltys SG, Moiseenko V, Redmond KJ et al (2021) Single- and multifraction stereotactic radiosurgery dose/volume tolerances of the brain. Int J Radiat Oncol Biol Phys 110(1):68–86
doi: 10.1016/j.ijrobp.2020.08.013
Jhaveri J, Chowdhary M, Zhang X, Press RH, Switchenko JM, Ferris MJ et al (2018) Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases. J Neurosurg 130(3):797–803
doi: 10.3171/2017.9.JNS171735
Blonigen BJ, Steinmetz RD, Levin L, Lamba MA, Warnick RE, Breneman JC (2010) Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 77(4):996–1001
doi: 10.1016/j.ijrobp.2009.06.006

Auteurs

Hendrick Tan (H)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.
GenesisCare, Perth, WA, Australia.

James Stewart (J)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.

Mark Ruschin (M)

Department of Radiation Oncology, University of Toronto, Toronto, Canada.
Department of Medical Physics, Sunnybrook Odette Cancer Centre, Toronto, Canada.

Michael H Wang (MH)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.

Sten Myrehaug (S)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Chia-Lin Tseng (CL)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Jay Detsky (J)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Zain Husain (Z)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Hanbo Chen (H)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Arjun Sahgal (A)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Hany Soliman (H)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada. hany.soliman@sunnybrook.ca.
Department of Radiation Oncology, University of Toronto, Toronto, Canada. hany.soliman@sunnybrook.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH